BB10 (BPC-157 + TB500) Co-Lyophilized Powder

Overview

BB10 combines two of the most extensively studied tissue repair peptides — BPC-157 (CAS 137525-51-0) and Thymosin Beta-4 / TB500 (CAS 885340-08-9) — co-lyophilized at a 1:1 ratio (5mg:5mg) in a single vial. For researchers studying multi-peptide tissue repair protocols, sourcing a co-lyophilized blend removes a practical variable: separate reconstitution of individual components introduces weighing error and potential concentration discrepancy between vials. Co-lyophilization ensures both peptides are processed under identical drying conditions, stored in the same vial, and reconstituted together in a single step from a single verified lot.

BPC-157 and Thymosin Beta-4 have complementary but mechanistically distinct profiles in the published literature. BPC-157 — a 15-amino acid synthetic peptide derived from the gastric protein Body Protection Compound — is studied primarily for its effects on angiogenesis, tendon and ligament repair, and gastrointestinal mucosal integrity. Thymosin Beta-4 — a 43-amino acid protein present in all mammalian cells — is characterized for its role in G-actin sequestration, endothelial cell migration, and systemic tissue remodeling. The mechanistic separation between these two compounds is a key reason researchers study them together: they target overlapping but non-identical pathways in tissue repair biology.

Component Profiles

BPC-157 (CAS 137525-51-0)
BPC-157 is a 15-amino acid synthetic pentadecapeptide (sequence: GEPPPGKPADDAGLV; MW ~1,419.5 g/mol) derived from the human gastric protein Body Protection Compound. Its primary characterized mechanisms include upregulation of growth factor receptors (VEGFR2, EGFR), promotion of angiogenesis through FAK-paxillin pathway activation, and modulation of nitric oxide synthesis. Published preclinical research covers gastrointestinal mucosal injury models, tendon-to-bone healing, and musculoskeletal recovery contexts.

Thymosin Beta-4 / TB500 (CAS 885340-08-9)
Thymosin Beta-4 is a ubiquitous 43-amino acid intracellular protein (MW ~4,963.4 g/mol) present in all mammalian cells. Its principal function is G-actin sequestration — binding monomeric actin to regulate the actin cytoskeleton and cell motility. In tissue injury contexts, extracellular Thymosin Beta-4 acts as a chemotactic signal for endothelial cells and myoblasts, promoting cell migration, angiogenesis, and tissue remodeling. The LKKTETQ motif within the sequence is the primary active region responsible for actin binding and angiogenic activity in published research models.

Mechanistic Rationale for the Combination

BPC-157 and Thymosin Beta-4 operate through mechanistically distinct angiogenic and repair pathways. BPC-157 promotes vascularization primarily through VEGF receptor signaling and nitric oxide-dependent mechanisms, with effects documented in early-phase tissue repair models. Thymosin Beta-4’s contribution to angiogenesis and cell migration is actin-cytoskeleton-dependent and spans the proliferative and remodeling phases of tissue repair. Researchers studying multi-phase repair protocols — where the vascularization, cell migration, and matrix remodeling phases occur sequentially — use this combination to model the full repair timeline rather than a single signaling window.

Chang et al.’s review in Current Pharmaceutical Design documents BPC-157’s angiogenic mechanisms and systemic tissue protection profile across multiple preclinical models [1]. Smart et al.’s work in Nature on Thymosin Beta-4’s role in endogenous cardiac progenitor cell activation following injury illustrates the breadth of Thymosin Beta-4’s tissue remodeling activity [2].

Technical Specifications

Quality & Documentation

Each batch of BB10 co-lyophilized powder is individually tested before shipment. Included with every order:

• HPLC purity verification for each component (BPC-157 and Thymosin Beta-4 resolved as individual peaks)
• Mass spectrometry (MS) identity confirmation for both components
• Batch number for full traceability

COA available upon request before order commitment.

Ordering Information

Browse our full peptide catalog:
Lyophilized Peptide Powders

FAQ

Q: What documentation is provided with each order?
Each order of BB10 includes a COA with HPLC purity data for both components (BPC-157 and Thymosin Beta-4 resolved as individual peaks), MS identity confirmation for both, and batch number. COA is available before order commitment upon request.

Q: Is there a minimum order quantity?
No minimum order is required. We supply any quantity — contact us for pricing and lead time on your specific order size.

Q: What is the difference between BB10, BB20, and BB30?
BB10, BB20, and BB30 are BPC-157 + Thymosin Beta-4 co-lyophilized blends at different per-vial quantities: BB10 contains 5mg + 5mg (10mg total), BB20 contains 10mg + 10mg (20mg total), and BB30 contains 15mg + 15mg (30mg total). All maintain the 1:1 ratio. The appropriate quantity depends on the scale of the research protocol and the required reconstituted concentration.

Q: Why source a co-lyophilized blend instead of individual peptides?
Co-lyophilized blends reduce reconstitution steps and eliminate inter-component weighing error when preparing multi-peptide protocols at consistent concentrations. For research institutions running standardized protocols across multiple operators, a pre-verified co-lyophilized blend provides a single-lot reference material with documented composition. Individual BPC-157 and Thymosin Beta-4 are also available separately from Vitaconin for researchers who require different component ratios.

Q: How should BB10 be stored?
Store unreconstituted vials at −20°C, sealed, protected from light and moisture. Shelf life is 24 months under proper conditions. Once reconstituted, use within the timeframe specified in the COA and store at 2–8°C.

Ready to Order?

Contact our team for pricing, COA, and shipping details. We respond within 24 hours.

Request This Product